Effect of angiosuppressive agents on renal cell carcinoma;Angiogenezisgátlók hatása metasztatikus vesesejtes rákban

Magyar Onkologia

Volumn 51, Issue 2, 2007, Pages 145-153

  Bodrogi, István ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; BEVACIZUMAB; DRUG DERIVATIVE; INDOLE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PROTEIN KINASE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

DRUG EFFECT; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; NEOVASCULARIZATION (PATHOLOGY); RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASES; PYRIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35748983559     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ottó Sz, Kásler M. A hazai és nemzetközi daganatos halálozási és megbetegedési mutatók alakulása. A népegészségügyi programok jellegzetességei és várható eredményei. Magyar Onkológia 49:99-107, 2005
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 353:2477-2490, 2005
3. Tímár J, Kopper L, Bodrogi I. A világossejtes veserák célzottterápiája és molekuláris patológiai alapjai. Magyar Onkológia 50:309-314, 2006
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
5. Kondagunta GV, Hudes GR, et al. Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): Results of a dose-finding study. ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5101, 2007
6. Patel PH, Kondagunta GV, et al. Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S): 5097, 2007
7. George DJ, Michaelson MD, et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Update results and analysis of circulating biomarkers. ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S): 2035, 2007
8. Feldman DR, Kondagunta GV, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5099, 2007
9. Srinivas S, Roigas J, et al. Continuous daily administration of sunitinib in patients with cytokinerefractory metastatic renal cell carcinoma (mRCC): Update results. ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5040, 2007
10. Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5106, 2007
11. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
12. Bracarda S, Porta C, et al. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-〈2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681. ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5100, 2007
13. Amato RJ, Harris P, et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5026, 2007
14. Plantade A, Choueiri T, et al. Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S)5037, 2007
15. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon alpha (IFN). ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5033, 2007
16. Yang JC, Haworth L, Sherry RM, et al. A Randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
17. Bukowski RM, Kabbinavar F, et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). ASCO Annual Meeting Proceedings. J Clin Oncol, 24(18S):4523. 2006
18. Escudier B, Koralewski P, et al. A randomized controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-〈2a as first-line therapy in metastatic renal cell carcinoma. ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):3, 2007
19. Garcia JA, Rini BI, et al. A phase II trial of low dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5103, 2007
20. Hutson TE, Davis ID, Machiels, JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5031, 2007
21. Jac J, Giessinger S, et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5107, 2007
22. Rini BI, Wilding GT, et al. Axitinib (AG-013736; AG) in patient (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. ASCO Annual Meeting Proceedings. J Clin Oncol 25(18S):5032, 2007
23. Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23:4162-4171, 2005